^
    Back
    Association details:
    Biomarker:SMAD4 positive
    Cancer:Pancreatic Adenocarcinoma
    Regimen:FOLFIRINOX (5-fluorouracil + irinotecan + leucovorin calcium + oxaliplatin)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancers (Basel)
    Title:

    SMAD4 Positive Pancreatic Ductal Adenocarcinomas Are Associated with Better Outcomes in Patients Receiving FOLFIRINOX-Based Neoadjuvant Therapy

    Published date:
    08/12/2023
    Excerpt:
    We retrospectively analyzed 59 patients from a single center who underwent surgical resection for primary PDAC after NAT….Interaction tests demonstrated that patients with SMAD4-positive tumors receiving FOLFIRINOX-based NAT showed the best outcome.
    DOI:
    10.3390/cancers15153765